Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Alnylam Pharmaceuticals's price to sales ratio was 4.4× on Nov 11, 2026, against 18.5× a year earlier. Over the last 5 years it ranged from 4.4× to 30.4×, with a median of 16.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.4× | −11.9 |
| 2025 | Dec 31, 2025 | 16.3× | +1.9 |
| 2024 | Dec 31, 2024 | 14.5× | +0.5 |
| 2023 | Dec 29, 2023 | 13.9× | −16.5 |
| 2022 | Dec 30, 2022 | 30.4× | +3.4 |
| 2021 | Dec 31, 2021 | 27.0× | −10.6 |
| 2020 | Dec 31, 2020 | 37.6× | −38.2 |
| 2019 | Dec 31, 2019 | 75.8× | −4.4 |
| 2018 | Dec 31, 2018 | 80.2× | +76.1 |
| 2011 | Jul 29, 2011 | 4.1× | +0.2 |
| 2010 | Dec 31, 2010 | 3.9× | – |
See a number that looks wrong?